Würzburg-based T-CURX at this time proclaims the primary closing of a €17.7 million Collection A to speed up medical improvement of T-CURX non-viral medical CAR-T therapies in AML and stable tumor indications, in addition to advancing T-CURX proprietary non-viral applied sciences for in vivo CAR-T era.
The Collection A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and that i&iBio Fund, as further traders together with present and new particular person traders.
Ulf Grawunder, PhD, co-founder and CEO of T-CURX, says: “I’m very excited that T-CURX attracted such a high-profile, worldwide investor’s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and medical CAR-T applied sciences and CAR-T pipeline packages, respectively. It’s a testomony of the top quality of T-CURX knowledge and the promise of our non-clinical and medical non-viral CAR-T pipeline in AML & CLL and stable tumor indications going after novel targets. It additionally highlights the excessive worth of our distinctive strategy to leverage non-viral CAR-vector and LNP applied sciences for extremely economical and scalable in vivo CAR-T era, with a purpose to ‘democratise’ CAR-T therapies for sufferers globally.”
In 2025, funding exercise factors to regular however selective funding exercise throughout Europe’s oncology and immuno-oncology panorama, offering context for T-CURX’s Collection A.
Alongside the German CAR-T developer, a number of different cancer-focused firms have secured funding this yr. In Switzerland, Hedera Dx raised €15 million in a Collection A to scale its precision oncology and diagnostics platform geared toward bettering entry to focused most cancers therapies. Finland-based TILT Biotherapeutics secured €22.6 million in a Collection B to advance medical improvement of its immuno-oncology candidates for stable tumours, whereas Dutch startup BIMINI Biotech closed a €3 million Seed spherical to progress small-molecule therapies for haematological cancers.
Taken collectively, these rounds characterize roughly €58 million in disclosed funding shifting by way of the European most cancers and immunotherapy sector in 2025. Inside this cohort, T-CURX’s Collection A ranks among the many bigger early-stage raises and stands out for its give attention to non-viral CAR-T applied sciences developed in Germany.
Aristotelis Nastos, PhD, Managing Accomplice and funding director at lead-investor BiomedVC provides: “I’m thrilled about main a extremely devoted worldwide syndicate of early-stage traders from Europe and Asia on this Collection A financing for T-CURX. We have been deeply impressed by the info on non-viral CAR-T product and know-how improvement at T-CURX, the track-record and expertise of T-CURX Founder’s and Administration workforce and the promise of T-CURX non-viral CAR-T applied sciences maintain for making CAR-T therapies accessible and inexpensive for a lot of most cancers sufferers globally.
“We’re very a lot wanting ahead to help T-CURX to realize all of their therapeutic and industrial ambitions.”
Based in 2017, T-CURX is a German BioTech firm spun-out of the laboratory of its co-founder, Prof. Michael Hudecek, College of Würzburg, who’s a European KOL and pioneer within the improvement and medical translation of non-viral CAR-T cell therapies to focus on numerous kinds of most cancers.
Their mission is to convey next-generation CAR-T cell therapies manufactured with cost-effective and extremely scalable non-viral CAR-T cell applied sciences to extra most cancers sufferers in want of simpler most cancers therapies.
T-CURX leverages a portfolio of proprietary non-viral CAR-T applied sciences for scalable and cost-effective CAR-T manufacturing primarily based on virus-free, Sleeping-beauty transposon gene switch into affected person’s T cells.
